Valneva Austria GmbH
Clinical trials sponsored by Valneva Austria GmbH, explained in plain language.
Vaccine development subsidiary of Valneva SE.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- 5,000 volunteers tracked to see if chikungunya vaccine is safe Results expected Oct 2026 (estimated)
-
Can a single shot shield children from chikungunya?
Vaccine CompletedThis trial is testing whether a single injection of an experimental chikungunya vaccine, VLA1553, is safe and triggers a protective immune response in healthy children aged 1 to 11 years. About 300 children will receive either a full dose, a half dose, or a control vaccine. The s…
Phase 2 • Sponsor: Valneva Austria GmbH • Aim: Vaccine
Last updated Aug 15, 2026 00:00 UTC
-
Zika vaccine candidate enters human safety testing
Vaccine CompletedThis early-stage trial tested an inactivated Zika virus vaccine (VLA1601) in 150 healthy adults aged 18-49. Participants received two doses, and researchers monitored side effects and immune responses. The goal was to find the safest and most effective dose, including combination…
Phase 1 • Sponsor: Valneva Austria GmbH • Aim: Vaccine
Last updated Jun 27, 2026 11:00 UTC